dabigatran has been researched along with eptifibatide in 1 studies
| Studies (dabigatran) | Trials (dabigatran) | Recent Studies (post-2010) (dabigatran) | Studies (eptifibatide) | Trials (eptifibatide) | Recent Studies (post-2010) (eptifibatide) |
|---|---|---|---|---|---|
| 3,887 | 261 | 3,490 | 907 | 220 | 212 |
| Protein | Taxonomy | dabigatran (IC50) | eptifibatide (IC50) |
|---|---|---|---|
| Integrin beta-3 | Homo sapiens (human) | 0.226 | |
| Integrin alpha-IIb | Homo sapiens (human) | 0.226 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abo Elmaaty, A; Abourehab, MAS; Al-Karmalawy, AA; Al-Rashood, ST; Alnajjar, R; Belal, A; Binjubair, FA; El-Taweel, AN; Eldehna, WM; Khattab, M; Kutkat, O; Saleh, MA | 1 |
1 other study(ies) available for dabigatran and eptifibatide
| Article | Year |
|---|---|
Anticoagulants as Potential SARS-CoV-2 M
Topics: Anticoagulants; Antiviral Agents; Coronavirus 3C Proteases; COVID-19 Drug Treatment; Dabigatran; Eptifibatide; Fondaparinux; Gentian Violet; Heparin; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; Protease Inhibitors; SARS-CoV-2; Ticagrelor; Viral Nonstructural Proteins | 2022 |